Cargando…
MiR-SNPs as Markers of Toxicity and Clinical Outcome in Hodgkin Lymphoma Patients
BACKGROUND: In recent years, microRNA (miRNA) pathways have emerged as a crucial system for the regulation of tumorogenesis. miR-SNPs are a novel class of single nucleotide polymorphisms that can affect miRNA pathways. DESIGN AND METHODS: We analyzed eight miR-SNPs by allelic discrimination in 141 p...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3660374/ https://www.ncbi.nlm.nih.gov/pubmed/23705004 http://dx.doi.org/10.1371/journal.pone.0064716 |
_version_ | 1782270555520499712 |
---|---|
author | Navarro, Alfons Muñoz, Carmen Gaya, Anna Díaz-Beyá, Marina Gel, Bernat Tejero, Rut Díaz, Tania Martinez, Antonio Monzó, Mariano |
author_facet | Navarro, Alfons Muñoz, Carmen Gaya, Anna Díaz-Beyá, Marina Gel, Bernat Tejero, Rut Díaz, Tania Martinez, Antonio Monzó, Mariano |
author_sort | Navarro, Alfons |
collection | PubMed |
description | BACKGROUND: In recent years, microRNA (miRNA) pathways have emerged as a crucial system for the regulation of tumorogenesis. miR-SNPs are a novel class of single nucleotide polymorphisms that can affect miRNA pathways. DESIGN AND METHODS: We analyzed eight miR-SNPs by allelic discrimination in 141 patients with Hodgkin lymphoma and correlated the results with treatment-related toxicity, response, disease-free survival (DFS) and overall survival (OS). RESULTS: The KRT81 (rs3660) GG genotype was associated with an increased risk of neurological toxicity (P = 0.016), while patients with XPO5 (rs11077) AA or CC genotypes had a higher rate of bleomycin-associated pulmonary toxicity (P = 0.048). Both miR-SNPs emerged as independent factors in the multivariate analysis. The XPO5 AA and CC genotypes were also associated with a lower response rate (P = 0.036). XPO5 (P = 0.039) and TRBP (rs784567) (P = 0.022) genotypes emerged as prognostic markers for DFS, and XPO5 was also associated with OS (P = 0.033). In the multivariate analysis, only XPO5 emerged as an independent prognostic factor for DFS (HR: 2.622; 95%CI 1.039–6.620; P = 0.041). Given the influence of XPO5 and TRBP as individual markers, we then investigated the combined effect of these miR-SNPs. Patients with both the XPO5 AA/CC and TRBP TT/TC genotypes had the shortest DFS (P = 0.008) and OS (P = 0.008). CONCLUSION: miR-SNPs can add useful prognostic information on treatment-related toxicity and clinical outcome in Hodgkin lymphoma and can be used to identify patients likely to be chemoresistant or to relapse. |
format | Online Article Text |
id | pubmed-3660374 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-36603742013-05-23 MiR-SNPs as Markers of Toxicity and Clinical Outcome in Hodgkin Lymphoma Patients Navarro, Alfons Muñoz, Carmen Gaya, Anna Díaz-Beyá, Marina Gel, Bernat Tejero, Rut Díaz, Tania Martinez, Antonio Monzó, Mariano PLoS One Research Article BACKGROUND: In recent years, microRNA (miRNA) pathways have emerged as a crucial system for the regulation of tumorogenesis. miR-SNPs are a novel class of single nucleotide polymorphisms that can affect miRNA pathways. DESIGN AND METHODS: We analyzed eight miR-SNPs by allelic discrimination in 141 patients with Hodgkin lymphoma and correlated the results with treatment-related toxicity, response, disease-free survival (DFS) and overall survival (OS). RESULTS: The KRT81 (rs3660) GG genotype was associated with an increased risk of neurological toxicity (P = 0.016), while patients with XPO5 (rs11077) AA or CC genotypes had a higher rate of bleomycin-associated pulmonary toxicity (P = 0.048). Both miR-SNPs emerged as independent factors in the multivariate analysis. The XPO5 AA and CC genotypes were also associated with a lower response rate (P = 0.036). XPO5 (P = 0.039) and TRBP (rs784567) (P = 0.022) genotypes emerged as prognostic markers for DFS, and XPO5 was also associated with OS (P = 0.033). In the multivariate analysis, only XPO5 emerged as an independent prognostic factor for DFS (HR: 2.622; 95%CI 1.039–6.620; P = 0.041). Given the influence of XPO5 and TRBP as individual markers, we then investigated the combined effect of these miR-SNPs. Patients with both the XPO5 AA/CC and TRBP TT/TC genotypes had the shortest DFS (P = 0.008) and OS (P = 0.008). CONCLUSION: miR-SNPs can add useful prognostic information on treatment-related toxicity and clinical outcome in Hodgkin lymphoma and can be used to identify patients likely to be chemoresistant or to relapse. Public Library of Science 2013-05-21 /pmc/articles/PMC3660374/ /pubmed/23705004 http://dx.doi.org/10.1371/journal.pone.0064716 Text en © 2013 Navarro et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Navarro, Alfons Muñoz, Carmen Gaya, Anna Díaz-Beyá, Marina Gel, Bernat Tejero, Rut Díaz, Tania Martinez, Antonio Monzó, Mariano MiR-SNPs as Markers of Toxicity and Clinical Outcome in Hodgkin Lymphoma Patients |
title | MiR-SNPs as Markers of Toxicity and Clinical Outcome in Hodgkin Lymphoma Patients |
title_full | MiR-SNPs as Markers of Toxicity and Clinical Outcome in Hodgkin Lymphoma Patients |
title_fullStr | MiR-SNPs as Markers of Toxicity and Clinical Outcome in Hodgkin Lymphoma Patients |
title_full_unstemmed | MiR-SNPs as Markers of Toxicity and Clinical Outcome in Hodgkin Lymphoma Patients |
title_short | MiR-SNPs as Markers of Toxicity and Clinical Outcome in Hodgkin Lymphoma Patients |
title_sort | mir-snps as markers of toxicity and clinical outcome in hodgkin lymphoma patients |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3660374/ https://www.ncbi.nlm.nih.gov/pubmed/23705004 http://dx.doi.org/10.1371/journal.pone.0064716 |
work_keys_str_mv | AT navarroalfons mirsnpsasmarkersoftoxicityandclinicaloutcomeinhodgkinlymphomapatients AT munozcarmen mirsnpsasmarkersoftoxicityandclinicaloutcomeinhodgkinlymphomapatients AT gayaanna mirsnpsasmarkersoftoxicityandclinicaloutcomeinhodgkinlymphomapatients AT diazbeyamarina mirsnpsasmarkersoftoxicityandclinicaloutcomeinhodgkinlymphomapatients AT gelbernat mirsnpsasmarkersoftoxicityandclinicaloutcomeinhodgkinlymphomapatients AT tejerorut mirsnpsasmarkersoftoxicityandclinicaloutcomeinhodgkinlymphomapatients AT diaztania mirsnpsasmarkersoftoxicityandclinicaloutcomeinhodgkinlymphomapatients AT martinezantonio mirsnpsasmarkersoftoxicityandclinicaloutcomeinhodgkinlymphomapatients AT monzomariano mirsnpsasmarkersoftoxicityandclinicaloutcomeinhodgkinlymphomapatients |